Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Allogene Therapeutics (ALLO) Interest Expenses (2024 - 2025)

Allogene Therapeutics (ALLO) has disclosed Interest Expenses for 2 consecutive years, with $313000.0 as the latest value for Q4 2025.

  • Quarterly Interest Expenses rose 286.42% to $313000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.1 million through Dec 2025, up 493.92% year-over-year, with the annual reading at $1.1 million for FY2025, 493.92% up from the prior year.
  • Interest Expenses hit $313000.0 in Q4 2025 for Allogene Therapeutics, down from $344000.0 in the prior quarter.
  • In the past five years, Interest Expenses ranged from a high of $344000.0 in Q3 2025 to a low of $81000.0 in Q4 2024.